You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Related Medications Videos on Diabetes Health TV
Easy to Use Insulin Delivery Patch
The World's First Diabetes Emergency Kit
A Product For When You Have Low Blood Sugar
Popular Actos Articles
Highly Recommended Actos Articles
The FDA has spoken: the heart risk warnings on labels of Avandia (rosiglitazone) and Actos (pioglitazone) will now be surrounded by an emphatic black outline known as a black box. Black boxes will also be added to the warnings on Avandaryl (rosiglitazone and glimepiride), Avandamet (rosiglitazone and metformin), and Duetact (pioglitazone and glimepiride).
3 comments - Oct 31, 2007 -
According to Greek researchers, Actos and Avandia were behind a tripling of the cost of medicines used to treat Athenians with type 2 diabetes over the past eight years.
0 comments - Oct 10, 2007 -
The September 2007 Journal of the American Medical Association (JAMA) has published two new studies, one a meta-analysis of Avandia (rosiglitazone) and the other a meta-analysis of Actos (pioglitazone).
0 comments - Oct 5, 2007 -
On July 30, 2007, a Food and Drug Administration (FDA) panel voted 22 to 1 to keep Avandia on the market, right after agreeing by a vote of 20 to 3 that Avandia does increase heart risks. Now the FDA will decide what kind of warning should appear on the Actos and Avandia labels. It has already called for a black box warning, the sternest possible, on Avandia.
0 comments - Aug 1, 2007 -
In a congressional hearing on June 13, 2007, the Food and Drug Administration (FDA) revealed that it has called for a black box warning, the sternest possible, on both Actos and Avandia.
0 comments - Jul 12, 2007 -
Analysis of several recent studies indicates that Avandia (rosiglitazone), a type 2 diabetes medication that's been taken by more than six million people worldwide, is associated with a 43 percent increased risk of heart attack and with a borderline-significant increased risk of heart attack-related death.
0 comments - May 31, 2007 -
New Zealand researchers say that in clinical trials of people with type 2 diabetes, Actos as stand-alone therapy or in combination with metformin, repaglinide, insulin or a sulphonylurea induced “both long- and short-term improvements in [blood glucose] control and serum lipid profiles.”
0 comments - Apr 1, 2006 - Not Yet Rated
It was the belle of the ball at last summer’s ADA Scientific Sessions in San Diego. Now it appears that muraglitazar (Pargluva) is clinging to life after a scathing report recently published by the Journal of the American Medical Association.
0 comments - Jan 1, 2006 - Not Yet Rated
In August 2005, Takeda Pharmaceuticals North America, Inc., announced that the U.S. Food and Drug Administration (FDA) had approved ACTOplus Met for the treatment of type 2 diabetes.
0 comments - Nov 1, 2005 - Not Yet Rated
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.